MiR-23b controls ALDH1A1 expression in cervical cancer stem cells

BMC Cancer

Research Article

Long Li¹  Yu Gao¹  Yang Li¹  Weiwen Wang²  Na Liu³ 

[1] Department of Gynecology and Obstetrics, First Affiliated Hospital, Xi’an Jiaotong University, 710061, 277 West Yanta Road, Xi’an, China;Department of Gynecology and Obstetrics, First Affiliated Hospital, Xi’an Jiaotong University, 710061, 277 West Yanta Road, Xi’an, China;Department of Neurosurgery, Tangdu Hospital, Fourth Military Medical University, Xi’an, China;Department of Ultrasound, The Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an, China;

关键词: miR-23b;    Cervical cancer stem cells;    ALDH1A1;   

DOI  :  10.1186/s12885-017-3192-x

 received in 2016-07-07, accepted in 2017-03-11,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundCancer stem cells has been widely investigated due to its essential role in cancer progression and drug resistance. Here, we try to find a new therapeutic target for cervical cancer stem cells.MethodsWe detected ALDH1A1-associated miRNAs expression in our isolated tumorspheres and their corresponding parental cells. Sphere formation assay was also used to determine stemness after cells were manipulated with miR-23b plasmid or miR-23b inhibitor.ResultsWe found that miR-23b was under-expressed in cervical cancer stem cells to maintain high levels of ALDH1A1. Introduction of miR-23b into cervical cancer cells could alter stemness and cisplatin sensitivity.ConclusionsmiR-23b plays key role in maintaining stemness of cervical cancer stem cells and can be developed as therapeutic target to better fight against cervical cancer.

【 授权许可】

CC BY   
© The Author(s). 2017